暂无推荐供应商。我要出现这里
化源商城直购
[1]. Melikyan AL, et al. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. Ter Arkh. 2018 Aug 17;90(7):23-29.
[2]. Znoyko OO, et al. Vozmozhnosti primeneniia tsepeginterferona al'fa-2b v sostave dvukh- (tsepeginterferon al'fa-2b i ribavirin) i trekhkomponentnoĭ (simeprevir, tsepeginterferon al'fa-2b i ribavirin) skhem protivovirusnoĭ terapii khronicheskogo gepatita S. Obzor klinicheskikh issledovaniĭ i opyta povsednevnoĭ klinicheskoĭ praktiki [Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice]. Ter Arkh. 2016;88(11):156-162. Russian.